NCI Donor-Derived FMC63-28Z CAR-T Phase 1 Trial Achieves Response in 8 of 20 Patients
Clinical Design and Development Objective
The NCT01087294 trial conducted by the National Cancer Institute (NCI) was a single-center, dose-escalation Phase 1 study targeting CD19-positive B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and lymphoma that had relapsed or persisted after allogeneic hematopoietic stem cell transplantation. The investigational therapy was an anti-CD19-CAR FMC63-28Z retroviral vector-transduced allogeneic T lymphocyte, which is a donor-derived anti-CD19 CAR-T not assigned to a commercial brand. The FMC63-derived single-chain variable fragment recognizes CD19 on B cells, while the CD28 costimulatory domain and CD3 zeta signaling domain drive T-cell proliferation and cytotoxic response. Initiated in 2010 and completed in April 2024, the long-term safety data were updated in November 2025.
Clinical Outcomes and Safety Signals
Published mature data showed that 8 of the 20 treated patients achieved a response, including 6 complete responses (CR) and 2 partial responses (PR). Notably, 4 of 5 acute lymphoblastic leukemia patients achieved minimal residual disease-negative complete remission, and responses were also observed in chronic lymphocytic leukemia and lymphoma. The longest complete remission duration exceeded 30 months in a chronic lymphocytic leukemia patient, and responders exhibited higher peak CAR-T levels than non-responders. Fever, tachycardia, and hypotension were the main toxicities, but no new-onset acute graft-versus-host disease (GVHD) occurred, clinically highlighting the reduced risk of unmanipulated donor lymphocyte infusion (DLI).
Standard Therapies and Competitive Landscape
Post-transplant relapse treatment includes DLI, chemotherapy, blinatumomab (Blincyto, a CD19-CD3 bispecific antibody), and inotuzumab ozogamicin (Besponsa, a CD22-targeting antibody-drug conjugate), forming disease-specific therapeutic axes. The CD19 CAR-T market includes Novartis (NVS)'s Kymriah (tisagenlecleucel), Gilead Sciences (GILD)'s Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), and Bristol Myers Squibb (BMY)'s Breyanzi (lisocabtagene maraleucel). FDA approvals were first granted to Kymriah on August 30, 2017, Yescarta on October 18, 2017, Tecartus on July 24, 2020, and Breyanzi on February 5, 2021, all of which are autologous products using the patient's own cells. Thus, the donor-derived approach in this study offers a differentiation point by reusing transplant donors, but its manufacturing model differs from off-the-shelf, ready-to-use products.
Market Potential and Development Interpretation
The global CAR-T therapy market reached USD 5.8 billion in 2025, with lymphoma accounting for 52.9% and North America for 61.1%. This study demonstrated antitumor activity with an 8-day manufacturing process, single-dose administration, and no requirement for lymphodepletion, suggesting potential to reduce manufacturing time and pretreatment burden. However, as a Phase 1 trial with 20 patients and mixed indications, it does not provide direct comparative evidence against commercial products and should be interpreted as an early platform study validating safety, cell expansion, and durability. The 2026 follow-up analysis showing stronger proliferation and persistence of stem cell memory CAR-T at lower doses directly informs next-generation donor-derived platform cell composition optimization.
From an investment perspective, this study provides early clinical validation that donor-derived manufacturing could differentiate itself from autologous cell-based products like Kymriah, Yescarta, Tecartus, and Breyanzi in the USD 5.8 billion CAR-T market in 2025. The 8 of 20 patient response rate and zero new-onset acute GVHD cases offer evidence of more precise immune attack in post-transplant relapse patients compared to DLI, but the mixed indications and small sample size remain constraints for commercial value estimation. For researchers, the correlation between in vivo CAR-T expansion and response, and the persistence of stem cell memory cells, are key data for subsequent product design and biomarker development. For the industry, the 8-day manufacturing and non-lymphodepletion dosing suggest potential for supply chain shortening, while multicenter confirmatory trials and standardized production processes remain key follow-up challenges.
Source: ClinicalTrials.gov (api_ct)